Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer

Benchmarks Nifty22,947.0558.1FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.7 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.39 % Invest NowEnter search text:

The Economic Times daily newspaper is available online now. Read Today's Paper Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancerPTILast Updated: Oct 21, 2026, 11:22:00 AM ISTSynopsis

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.

New Delhi: Dr Reddy's Laboratories on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), through which it aims to expand access to first-line immunotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) in India.

The drug has been approved in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC, the pharma company said in a release.

Also Read: Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV Prasad

This marks Zytorvi's second approved indication in the country, expanding beyond nasopharyngeal carcinoma.

ESCC accounts for approximately 80 per cent of all esophageal cancer cases in India, the company said.

Live Events

Zytorvi contains toripalimab, a monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, thereby supporting T-cell activity against cancer cells.

The approval is supported by results from the Phase 3 JUPITER-06 trial. In the study, toripalimab in combination with paclitaxel and cisplatin reduced the risk of disease or death by 42 per cent compared with chemotherapy alone, according to the release.

Also Read: Dr Reddy’s aims to resume semaglutide supply by November after API fix

At the final overall-survival analysis, median overall survival was 17.7 months with toripalimab plus chemotherapy compared with 12.9 months with chemotherapy alone, it added.

Dr. Reddy's holds commercialisation rights for toripalimab across 21 countries under a 2023 agreement with Junshi Biosciences.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News ondr reddy's laboratoriesDr Reddy's LaboratoriesZytorviesophageal cancerimmunotherapytoripalimabadvanced esophageal squamous cell carcinomaDCGI approval

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News ondr reddy's laboratoriesDr Reddy's LaboratoriesZytorviesophageal cancerimmunotherapytoripalimabadvanced esophageal squamous cell carcinomaDCGI approval

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless

Stories you might be interested in